A new method for predicting the risk of chronic kidney disease (CKD) progression and cardiovascular complications is showing promise, offering a potential lifeline to the more than 20 million people in Japan—and millions more worldwide—affected by these interconnected conditions. Researchers at the Institute of Science Tokyo have developed a technique that analyzes tiny RNA molecules, known as microRNAs, found within extracellular vesicles in the bloodstream to assess a patient’s long-term risk. This breakthrough in predicting cardiovascular complications in chronic kidney disease could lead to earlier interventions and improved patient outcomes.
Chronic kidney disease often doesn’t present noticeable symptoms in its early stages, yet it significantly elevates the risk of heart disease and stroke. This complex interplay between kidney health, cardiovascular function, and metabolic processes is often referred to as cardiovascular-kidney-metabolic (CKM) syndrome. Currently, accurately predicting which CKD patients will experience rapid disease progression or develop serious cardiovascular problems remains a significant clinical challenge. The new microRNA-based method aims to fill this critical gap.
The research, led by Associate Professor Shintaro Mandai, Doctoral Student Shunsuke Inaba, and Professor Shinichi Uchida from the Graduate School of Medical and Dental Sciences, Institute of Science Tokyo, in collaboration with Associate Professor Takanori Hasegawa from the M&D Data Science Center, Institute of Integrated Research, Institute of Science Tokyo, involved analyzing blood samples to identify specific microRNA signatures associated with disease progression. These microRNAs, carried by extracellular vesicles, act as messengers, reflecting the underlying health status of the kidneys and cardiovascular system. The team’s findings were published in the JAHA: Journal of the American Heart Association on January 6, 2026.
How MicroRNAs Predict Risk
MicroRNAs are small, non-coding RNA molecules that play a crucial role in regulating gene expression. Their levels in the bloodstream can change in response to various diseases, making them potential biomarkers. Extracellular vesicles are tiny packages released by cells that transport molecules, including microRNAs, throughout the body. By profiling these microRNAs using microarray technology, the researchers were able to construct predictive models for both CKD progression and cardiovascular events. The study framework, as outlined by the research team, involves a workflow from the initial microRNA profiling to the validation of these predictive models. More details on the study design are available from the Institute of Science Tokyo.
The team identified a panel of microRNAs that were strongly correlated with the development and worsening of both kidney disease and cardiovascular issues. This allowed them to create a model capable of distinguishing between patients at high and low risk. The ability to accurately identify high-risk individuals is crucial for tailoring treatment strategies and implementing preventative measures.
Translating Research into Clinical Practice
The next step for the researchers is to translate this technology into a practical risk score that can be routinely used in clinical settings. “Going forward, the team aims to translate this technology into a risk score that can be routinely applied in clinical settings, with the goal of improving prognosis for CKD patients,” according to the Institute of Science Tokyo. Such a score would allow doctors to proactively manage patients at higher risk, potentially through more frequent monitoring, lifestyle interventions, or targeted therapies.
The potential benefits of this approach extend beyond improved patient care. By identifying individuals at risk before they experience severe complications, healthcare systems could potentially reduce the overall burden of CKD and cardiovascular disease, leading to cost savings and improved public health. The research highlights the growing importance of personalized medicine, where treatment strategies are tailored to an individual’s unique biological profile.
Understanding Extracellular Vesicles and MicroRNAs
Extracellular vesicles (EVs) are released by all types of cells and circulate in bodily fluids like blood, urine, and saliva. They contain a variety of molecules, including proteins, lipids, and nucleic acids, such as microRNAs. These vesicles act as a communication network between cells, delivering their cargo to distant sites. Further information on extracellular vesicles and microRNAs can be found in a recent publication detailing their role in kidney-metabolic syndrome.
MicroRNAs, specifically, are involved in regulating gene expression, influencing a wide range of cellular processes. Changes in microRNA levels can reflect underlying disease states, making them valuable biomarkers for diagnosis and prognosis. The stability of microRNAs within extracellular vesicles also protects them from degradation, making them ideal candidates for liquid biopsy applications – analyzing biomarkers in easily accessible bodily fluids.
What This Means for Patients with CKD
For individuals living with chronic kidney disease, this research offers a glimmer of hope. Currently, managing CKD often involves addressing symptoms and slowing disease progression. However, the ability to accurately predict future cardiovascular risk could empower patients and their doctors to make more informed decisions about treatment and lifestyle modifications. This could include more aggressive blood pressure control, cholesterol management, and dietary changes.
Even as the microRNA-based risk score is not yet available for routine clinical employ, the research represents a significant step forward in the fight against CKD and its associated cardiovascular complications. The team at the Institute of Science Tokyo is actively working to refine the model and validate its performance in larger, more diverse patient populations. The ultimate goal is to provide a reliable and accessible tool that can improve the lives of millions affected by this debilitating condition.
The researchers plan to continue their work, focusing on refining the risk score and conducting further studies to validate its effectiveness across different populations. Updates on the progress of this research will be available through the Institute of Science Tokyo and publications in peer-reviewed medical journals.
Disclaimer: This article is for informational purposes only and should not be considered medical advice. Please consult with a qualified healthcare professional for any health concerns or before making any decisions related to your health or treatment.
Have you or a loved one been affected by chronic kidney disease? Share your thoughts and experiences in the comments below. Please also share this article with anyone who might find it helpful.
